Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Insulin like growth factor I (IGFI) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprote...

Full description

Saved in:
Bibliographic Details
Published in:Growth hormone & IGF research 2023-08, Vol.71, p.101548-101548, Article 101548
Main Authors: Laron, Zvi, Werner, Haim
Format: Article
Language:English
Subjects:
Atherosclerotic cardiovascular disease
IGF-I
IGF-treatment
Lipoprotein(a)
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Insulin like growth factor I (IGFI) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered. •Insulin-like growth factor (IGFI), the anabolic effector of growth hormone, reduces the synthesis of lipoprotein (a).•The Lp(a) reducing effect of IGF-I could serve as primary or adjunctive treatment for hyperproteinemia, a risk factor for atherosclerotic cardiovascular disease.
ISSN:1096-6374
1532-2238
DOI:10.1016/j.ghir.2023.101548